EBIT: Income before interest and taxes.
NeuroSense Therapeutics Ltd. (NRSN) had EBIT of $-11.09M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-11.12M |
|
-- |
|
-- |
|
$11.09M |
|
$-11.09M |
|
$-0.04M |
|
$-11.12M |
|
$-11.12M |
|
$-11.12M |
|
$-11.12M |
|
$-11.12M |
|
$-11.12M |
|
|
EBIT |
$-11.09M |
$-11.07M |
|
25.48M |
|
25.48M |
|
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$0.78M |
|
$0.06M |
|
$0.25M |
|
$1.03M |
|
$2.52M |
|
$0.07M |
|
$0.07M |
|
$2.59M |
|
$-1.56M |
|
$-1.56M |
|
$-1.56M |
|
32.56M |
|
| Cash Flow Statement Financials | |
$-7.67M |
|
$-0.01M |
|
$4.43M |
|
$3.38M |
|
$0.17M |
|
$-3.21M |
|
$2.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.31 |
|
-- |
|
-- |
|
-0.05 |
|
-0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.68M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
713.14% |
|
713.14% |
|
-1082.20% |
|
747.65% |
|
$-0.05 |
|
$-0.30 |
|
$-0.30 |
|